Biophytis SA · EURONEXT:ALBPS
Biophytis SA — Investor Presentation (March 2026)
21 slides from Biophytis SA's investor presentation, March 2026

Slide 1: A pioneering biotechnology company focused on therapies that impact longevity
A pioneering biotechnology company focused on developing transformative therapies that impact longevity Founded on pioneering science from researchers at

Slide 2: A pioneering biotechnology company focused on therapies that impact longevity
A pioneering biotechnology company focused on developing transformative therapies that impact longevity Founded on pioneering science from researchers at

Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as «outlook », «believes», «expects», «potentia

Slide 4: Mission & Vision
Blophytis Mission & Vision Advancing Longevity by discovering new targets and drug candidates addressi fundamental needs in human aging

Slide 5: Our leadership team has a proven track record
Our leadership team has a proven track record across drug discovery, development, and commercialization Management Committee Cumulative years of experience Broad Experience in BioPharma and beyond S tan isla s Ve illet C hief E xec utive O fficer E do ua rd Bieth C hief S trateg y O fficer 176y 126y

Slide 6: Our Strategic R&D programs
Our 3 Strategic R&D programs Our Longevity Research Platform BIO101 in Sarcopenia BIO101 in Obesity A unique platform combining The world’s most advanced A unique program targeting several technologies accelerated by clinical program in sarcopenia mobility in patients suffering AI for the discovery

Slide 7: Our Longevity Research Platform
Our Longevity Research Platform BIO101 in Sarcopenia BIO101 in Obesity

Slide 8: Our Longevity Research Platform: new therapeutic solutions
Our research explores and identifies the Our Longevity Research Platform fundamental mechanisms of aging to develop new therapeutic solutions… Alzheimer’s Frailty and Disease and Cardiovascular Muscular Dementia Diseases diseases Diabetes Chronic Osteoarthritis and Obstructive Osteoporosis Pulmonary

Slide 9: Our research has developed unique R&D capabilities
Our research has developed Our Longevity Research Platform unique R&D capabilities Target ID & validation Technology Assessment and Lead ID Screening and Candidate selection Exploration Expertise across discovery and development with a We use 2 types of screening Methods : and identification unique

Slide 10: BIO101 in Sarcopenia
Our Longevity Research Platform BIO101 in Sarcopenia BIO101 in Obesity

Slide 11: BIO101: oral small molecule drug candidate
BIO101 : Our drug candidate is an oral small molecule potential for best in class acting on the root cause of muscle wasting First in class molecule Ease of administration • Validated mechanism of action • API manufactured at industrial scale • Activation of MAS receptor (protective • Advanced CMC a

Slide 12: Sarcopenia, an exploding market with no therapeutic solution
Sarcopenia, an exploding market with no BIO101 in Sarcopenia therapeutic solution as of today No pharmacological treatment Sarcopenia is a disorder defined has yet been approved, only consensually by several limited options exist consortia (FNIH, EWGSOP, SDOC and ESCEO), characterized by up to 1/4 p

Slide 13: BIO101 is the most advanced drug candidate in sarcopenia
BIO101 is the most advanced drug candidate BIO101 in Sarcopenia in sarcopenia Administration Drug Company Technology Main Endpoints Safety & Side effects Status route High Dose showed Excellent tolerability Phase 3 BIO101 MAS Receptor promising results on profile and no serious oral to start (20 hyd

Slide 14: In Phase 2, BIO101 improved mobility of sarcopenia patients
In Phase 2, BIO101 improved mobility BIO101 in Sarcopenia of patients suffering from sarcopenia BIO101 350mg BID versus placebo : Gait Speed Improvement Fielding 2025 et al. Journal of Cachexia, Sarcopenia and Muscle, 2025; 16:e13750 +11%

Slide 15: Partnership Formation in Asia
We aim at conducting the first Phase 3 ever in sarcopenia to confirm the clinical efficacy of BIO101 BIO101 in Sarcopenia in a larger population Targeted Indication Treatment of severe sarcopenia in older patients (≥65 years) who are at risk of mobility disability Partneship Formation in Asia ➢ Crea

Slide 16: BIO101 in Obesity: 96% of obese patients have mobility issues
The vast majority of patients suffering from BIO101 in Obesity Obesity have mobility issues 96% of obese patients have impaired muscle strength(2) (1) https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth (2) Vale nzuela et al. BMC Musculoskeletal Disorders

Slide 17: A unique program targeting mobility in patients suffering from obesity
A unique program targeting mobility in BIO101 in Obesity patients suffering from obesity Strong Proof of concept (1) A Phase 2 targeting muscle quality in obesity Partnership established Sample size : 164 patients License agreement in LATAM signed with BLANVER Target population: PHARMA Obese patient

Slide 18: Major upcoming milestones on our R&D programs
Major upcoming milestones on our 3 R&D programs Our Longevity Research Platform BIO101 in Sarcopenia BIO101 in Obesity ACHIEVED ACHIEVED ACHIEVED ✓ Partnership signed with LYNX Analytics in AI ✓ Trial readiness : work preparation with CROs ✓ BIO101 + GLP-1 animal studies results ✓ Protocol to identi

Slide 19: Our Pipeline: Transformative therapies that impact longevity
Our Pipeline: Transformative therapies that impact longevity IND Candidate Indication Program Discovery Lead Op Enabling Phase 1 Phase 2 Phase 3 Registration Strategic Programs BIO101 Sarcopenia SARA BIO101 Obesity OBA Target Multiple Discovery Targets BIO101 Covid 12 COVA other projects BIO101 DMD

Slide 20: Financial data
Financial data Shareholding structure Key financials Listing Euronext (ALBPS) and US market (OTC) Institutional Investors US* 15% 17% ▪ Cash position: €1,.2M (June 30th, 2025) 31% ▪ Debt conversion: €2m commitment from 10% BlackRock and Atlas Floating 61 % and Others Analyst Coverage Institutional 2

Slide 21: Our three strategic programs summary
Our Longevity Research Platform A unique platform combining several technologies accelerated by AI for the discovery of new drug candidates impacting longevity Mission & Vision BIO101 in Sarcopenia The world’s most advanced clinical program in sarcopenia BIO101 in Obesity A unique program targeting
Source: company website
More decks from Biophytis SA
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (March 2026)21 slides · March 2026
Investor Presentation (January 2025)32 slides · January 2025
Investor Presentation (December 2024)48 slides · Dec 6, 2024
Investor Presentation (May 2024)43 slides · May 2024